New cancer drug injected directly into tumors shows promise in early trial
NCT ID NCT05383170
Summary
This early-stage study tested a new drug, CyPep-1, which is injected directly into tumors. It was combined with the immunotherapy drug pembrolizumab to see if it could help control advanced head and neck cancer, melanoma, or triple-negative breast cancer. The main goals were to check the safety of this combination and see if it could shrink tumors by potentially boosting the body's immune response against cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HM - Hôpital de la Timone
Marseille, France
-
Azienda Ospedaliero Universitaria Senese
Siena, Italy
-
CHRU de Besançon
Besançon, France
-
CHU Lille
Lille, France
-
Centre Leon Berard
Lyon, France
-
City Of Hope
Duarte, California, 91010, United States
-
Clinica Universidad de Navarra Madrid
Madrid, Spain
-
Clinica Universidad de Navarra Pamplona
Pamplona, Spain
-
EMC
Rotterdam, Netherlands
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
Hospital Universitario HM Sanchinarro
Madrid, Spain
-
Hospital Universitario Virgen Macarena
Seville, Spain
-
Houston Methodist
Houston, Texas, 77030, United States
-
Hôpital Saint Louis - AP-HP
Paris, France
-
Institut Bergonie
Bordeaux, France
-
Institut Paoli Calmettes
Marseille, France
-
Institute Gustave Roussy
Villejuif, France
-
Istituto Europeo di Oncologia
Milan, Italy
-
Maastricht UMC
Maastricht, Netherlands
-
NKI/AvL
Amsterdam, Netherlands
-
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213-2582, United States
-
Vall d'Hebron (VHIO)
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.